Current market catalysts

UBS Maintains Buy on Repligen, Raises Price Target to $225

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.

- Apple: Announces Foldable Design Of iPhone; Apple Says Foldable Design Will Have Two Cameras; Announces Foldable iPhone Named iPhone Duo

https://www.apple.com/apple-events/event-stream/

Raymond James Maintains Outperform on Solaris Energy Infr, Raises Price Target to $96

Raymond James analyst J.R. Weston maintains Solaris Energy Infr (NYSE:SEI) with a Outperform and raises the price target from $82 to $96.

TurboGen shares are trading lower. The company announced a business consulting and development agreement with a strategic group including Former New York City Mayor Eric Adams.

UBS Maintains Buy on Natera, Raises Price Target to $435

UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.

Needham Reiterates Buy on Barnes & Noble Education, Maintains $16 Price Target

Needham analyst Ryan MacDonald reiterates Barnes & Noble Education (NYSE:BNED) with a Buy and maintains $16 price target.

Raymond James Maintains Strong Buy on Expand Energy, Raises Price Target to $147

Raymond James analyst John Freeman maintains Expand Energy (NASDAQ:EXE) with a Strong Buy and raises the price target from $145 to $147.

BTIG Reiterates Buy on SailPoint, Maintains $21 Price Target

BTIG analyst Gray Powell reiterates SailPoint (NASDAQ:SAIL) with a Buy and maintains $21 price target.

UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.

8-K filing — Federal Home Loan Bank of Des Moines

Filed: 2026-09-09 AccNo: 0001325814-26-000142 Size: 184 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Apple Watch Series 12 Starts At The Same Price Of $399, And Apple Watch Ultra 4 Remains At $799; Says Apple Watch Series 12 And Apple Watch Ultra 4 Can Be Pre-Ordered Starting Today, Available On September 18th

https://www.apple.com/apple-events/event-stream/

Raymond James Maintains Outperform on Braze, Raises Price Target to $33

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $27 to $33.

UBS Maintains Buy on Guardant Health, Raises Price Target to $225

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.

HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.

Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.

Apple Introduces Audio Intelligence; Introduces Live Rewind Feature To Transcribe 15 Seconds Of Recent Audio; Apple Introduces Siri Recap To Summarize Conversations; Apple Says Audio Intelligence Features Do Not Create Or Store Audio Files; Introducing Audio Intelligence To Bring Sound Recognition To Apple Watch

Global Access or Regulatory Risk? Robinhood Accelerates Crypto-Linked Strategy

Robinhood CEO Vlad Tenev defends 1:1 backed stock tokenization as Needham analysts signal a crypto bottom and long-term growth potential for HOOD.

UBS Maintains Sell on Comstock Resources, Raises Price Target to $14

Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

What's Going On With Cipher Digital Stock Wednesday?

Cipher Digital (CIFR) drops 8% to $16.99 amid market drag. Key technical levels: $16 support and $18 resistance.

UBS Maintains Neutral on Chime Financial, Raises Price Target to $31

UBS Maintains Buy on Braze, Raises Price Target to $32

Roth Capital Initiates Coverage On Pasqal Holding with Buy Rating, Announces Price Target of $20

UBS Maintains Neutral on Bruker, Raises Price Target to $65

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.

Argan shares are trading lower after Piper Sandler initiated coverage on the stock with an Underweight rating and announced a $273 price target.

Apple Announces Apple Watch Series 12 And Apple Watch Ultra 4

Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

Knife River shares are trading lower after Wells Fargo lowered its price target on the stock from $73 to $62.

Morgan Stanley Upgrades Lineage to Overweight, Maintains Price Target to $47